Endoscopic Full-Thickness Plication Efficacious for GERD
By Elana Gotkine HealthDay Reporter
FRIDAY, Dec. 6, 2024 -- Endoscopic full-thickness plication (EFTP), which improves the valvular mechanism of the gastroesophageal junction, is efficacious for managing gastroesophageal reflux disease (GERD) symptoms, according to research published in the November issue of JGH Open.
Muhammad Shahzil, M.D., from Weiss Memorial Hospital in Chicago, and colleagues conducted a meta-analysis to compare EFTP to a sham procedure for treatment of refractory GERD. Three randomized controlled trials with 272 patients were included: 136 of the patients underwent EFTP and 136 had sham procedures.
The researchers observed a significant reduction in proton pump inhibitor usage (risk ratio, 0.51) and a significant improvement in GERD-health-related quality of life scores at three months (risk ratio, 15.81). There was no significant difference in the DeMeester scores. No significant difference was seen in time with esophageal pH <4; however, there was a significant reduction noted in total reflux episodes.
"Our findings contribute to the evidence base, but further research comparing EFTP to other minimally invasive techniques is crucial for obtaining comprehensive evidence," the authors write. "Such research will continue to inform clinical decisions and help clinicians decide the most suitable treatment options tailored to individual patients."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-07 06:00
Read more
- 1990 to 2021 Saw Decline in Life Expectancy in the United States
- Researchers Uncover New Role of Mutant Proteins in Some of the Deadliest Cancers
- FDA Approves Bimzelx for Hidradenitis Suppurativa
- Celiac Disease Linked to Higher Risk for Developing Alopecia Areata
- Amgen Announces Robust Weight Loss With MariTide in People Living With Obesity or Overweight at 52 Weeks in a Phase 2 Study
- Greater Fine Particulate Matter Linked to Increased Odds of Eczema
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions